Text Resize

[Urgent] Cancer Drugs That Give You…Cancer?!

When you’re diagnosed with cancer, the last thing you expect is for the treatment itself to trigger another cancer.

But that’s exactly what’s happening with a widely used cancer drug recently pulled from the global market.

Doctors once hailed it as a targeted therapy breakthrough, fast-tracked for approval in serious cancers. Patients trusted it, thinking it was their lifeline.

Then the shock came.

New data from post-approval trials revealed patients taking the drug were developing secondary blood cancers—the very thing the drug was supposed to prevent.

In other words… a treatment meant to save lives has been putting patients at risk all this time.

If you or a loved one is facing cancer treatment, could you be taking a drug that’s actually making things worse—without even knowing it?

The drug in question is tazemetostat.

It had been prescribed for a type of non-Hodgkin lymphoma and a rare soft-tissue cancer, earning FDA accelerated approval in 2020.

Accelerated approval is meant to give patients early access to promising therapies—but it comes with a catch…

We have no idea about the long-term safety of a drug at the time of approval.

And in this case, the other shoe dropped.

The post-approval trial—called SYMPHONY‑1—uncovered that patients on tazemetostat had higher rates of secondary blood cancers than those receiving standard therapy alone.

That revelation forced the manufacturer to withdraw the drug worldwide, announced on March 9, 2026.

And tazemetostat is far from an isolated case. Several oncology drugs have been withdrawn after post-market studies revealed serious side effects or even new cancers that didn’t appear in initial trials.

This raises an uncomfortable but critical question:

How many “miracle” drugs are approved before we fully understand their long-term risks?

With the pressure and influence Big Pharma has within our government, too often the FDA’s policy has been to approve first, ask questions later.

But cancer patients deserve complete transparency about the trade-offs—especially when we don’t know the long-term risks of a drug, or whether it could be setting them up for another disease down the road.

First off, if you or a loved one is taking tazemetostat, talk to your doctor right away. He needs to get you onto another treatment program.

And anytime you or a loved one faces cancer therapy, ask the tough questions:

  • Is it possible that there are long-term risks that haven’t fully emerged yet?
  • Was the drug fast-tracked and are confirmatory studies still being done?
  • Are safer alternatives available? (we’ll be sure to keep you in the know)

Because surviving cancer isn’t just about treating the first disease. It’s about making sure the cure doesn’t become the next one.

To knowing the whole story,

Ray Thatcher
Research Director, Health Sciences Institute

Sources:

  |   Back to top   |  

Recent Articles:

Load More Articles
Allan Spreen, M.D.
Dr. Allan Spreen, Chief Medical Advisor

Meet the Health Sciences Institute

The Health Sciences Institute (HSI) is an independent organization established in 1998. We’re dedicated to uncovering and researching the most urgent advances in modern underground medicine. Things you WON’T hear about in the mainstream.

Whether they come from a laboratory in Malaysia, a clinic in South America, or a university in Germany, our goal is to bring the treatments that work directly to the people who need them. We alert our Members to exciting breakthroughs in medicine, show them exactly where to go to learn more, and help them understand how they and their families can benefit from these powerful discoveries.

Learn More About the Health Sciences Institute. >